Dec. 24 at 7:31 PM
Thermo Fisher Scientific has been named Bank of America’s top pick in the Life Sciences Tools space, with the firm raising its price target to
$700 and reaffirming a Buy rating. Management projects 3–4% revenue growth in fiscal 2026 and more than 50 basis points of operating margin expansion, excluding benefits from the Clario acquisition, which is expected to add about
$0.45 in EPS in its first year. The company is positioned to benefit from favorable industry trends such as reshoring and reduced uncertainty across academic, government, and pharmaceutical markets, while continued innovation and its “trusted partner” strategy should sustain momentum.
Recently, Thermo Fisher has seen multiple positive analyst actions, including an upgrade to Overweight from KeyBanc and new Overweight or Buy ratings from Morgan Stanley and Goldman Sachs. The company also announced an expansion of its bioprocessing capabilities across Asia to support the region’s growing biopharmaceutical industry.
$TMO